Publications
Protocol
PC-COS 'HOW' Stage Protocol AMENDMENTS
The amendment to original PC-COS 'HOW' Protocol: changes to protocol, dates of change, reasons for changes, etc.
View
Protocol
PC-COS 'HOW' Stage Protocol
Now that we have defined a COS for Post COVID-19 condition on the outcome domain level (i.e. WHAT to measure), it is important to achieve consensus on HOW these domains should be
measured, i.e., which outcome measurement instruments should be selected. When using the term ‘instrument,’ we are referring to any outcome measurement instruments, tools, procedures, etc., that are used to measure an outcome domain...
View
Position Paper                   

A Core Outcome Set for post-COVID-19 Condition in adults for use in clinical practice and research: An International Delphi Consensus Study

Recent data suggest that many people experience Post COVID-19 Condition (Long COVID) following the acute phase of the SaRS CoV-2 infection. At present there is no agreement on what patient health outcomes should be measured in Post COVID-19 Condition. We aimed to identify core outcomes for Post COVID-19 Condition that stakeholders considered critical to assess in all research studies and clinical practice.
Learn more
Podcast
In conversation with... 
The Lancet Respiratory Medicine Podcast
Daniel Munblit and Dale Needham discuss the importance of developing a core outcome set for post-COVID-19 condition.

The Lancet Respiratory Medicine Podcast Editors speak to the journal’s authors to explore their research and its impact on people’s health, health care, and health policy in this regular podcast.
Listen
Opinion
Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development
A substantial portion of people with COVID-19 subsequently experience lasting symptoms including fatigue, shortness of breath, and neurological complaints such as cognitive dysfunction many months after acute infection. Emerging evidence suggests that this condition, commonly referred to as long COVID but also known as post-acute sequelae of SARS-CoV-2 infection (PASC) or post-COVID-19 condition, could become a significant global health burden.
Learn more
PC-COS Children Comment
Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development
Although the prevalence of post-COVID-19 condition in children and young people might be lower than in adult populations, the impact on physical and psychological health could be lifelong, not only creating increased demands on health services but also having wider socioeconomic implications for the affected children and society—eg, by adversely affecting career opportunities and earnings, productivity, and economics, as well as social activities, relationships, and longevity. There is an urgent need to initiate projects that aim to develop a COS and associated measurements.
Learn more
COMET REGISTRATION
Core Outcome Measures for Post-Covid condition/Long Covid study registration in Core Outcome Measures in Effectiveness Trials (COMET) database
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed a significant burden on public health worldwide. As of end of March 2021, there have been an estimated 125 million cases of coronavirus disease 2019 (COVID-19) globally. The acute presentation of COVID-19 has now been widely investigated and risk factors for in-hospital mortality identified.

It has now become evident that a significant portion of those with COVID-19 subsequently experience lasting symptoms including fatigue, breathlessness and neurological complaints months after the acute infection. This is now commonly referred to as Long COVID but has also been described as post-COVID syndrome or COVID long-haulers. Recently published the UK National Institute for Health and Clinical Excellence (NICE) COVID-19 guideline call infection sequalae “Post-COVID-19 syndrome”, defining it as “signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis”. Interim definitions for the COVID-19 sequelae are, however, based on limited evidence from small cohorts with short-term follow-up. The World Health Organization at a recent global forum called countries to prioritise rehabilitation for the consequences of COVID-19, collect harmonised information on Long Covid and proposed the term “Post-Covid condition”.

There is an urgent need to optimise and standardise outcome measures for this important and emerging patient group both for clinical services and for research, especially clinical trials, to allow comparing and pooling of data. The aim of this project is to rapidly define a core outcome set (COS) for Post-Covid condition/Long Covid for both clinical (from low to high resource settings) and research use.

Contributors
Daniel Munblit, Sechenov University, Moscow, Russia/ Imperial College London, London, UK
Timothy Nicholson, King's College London, London, UK
Paula Williamson, University of Liverpool, UK
Christian Apfelbacher, University of Magdeburg, Germany
Piero Olliaro, ISARIC, University of Oxford, UK
Theo Vos, University of Washington, Seattle, USA
Margaret Herridge, University of Toronto, Canada
Dale Needham, Johns Hopkins University, USA
John Marshall, University of Toronto, Canada
Louise Sigfrid, ISARIC, University of Oxford, UK
Jochen Schmitt, University Dresden, Germany
Frances Simpson, University of Coventry, UK
Calum Semple, University of Liverpool, UK
John O Warner, Imperial College London, London, UK
Allison Tong, The University of Sydney, Australia
Janet Scott, University of Glasgow, UK
Jon Genuneit, University of Leipzig, Germany
Nina Seylanova, Sechenov University, Moscow, Russia
Alisa Kokorina, Pirogov University, Moscow, Russia
Callum Parr, Imperial College London, London, UK
Jessica Chen, Imperial College London, London, UK
Alla Guekht, Research and Clinical Center for Neuropsychiatry, Moscow, Russia
Audrey DunnGalvin, University of Cork, Ireland
Wouter De Groot, World Health Organization

Further Study Information
Current Stage: Ongoing
Date: March 2021 - March 2022
Funding source(s): No external funding
Made on
Tilda